Clinical Trials Browser

OTHER × infigratinib × Breast × Clear all

NCT04504331 2026-02-12

Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

Phase 1 Terminated

4 enrolled 11 charts

Breast Neoplasms